NSC, Sanofi, and A*STAR partner to advance acne treatment research

The collaboration includes a phase 1 clinical study to start in the second quarter of 2025.

The National Skin Centre Singapore, Sanofi, and the Agency for Science, Technology, and Research (A*STAR) have signed a memorandum of understanding (MoU) to advance research in acne treatment.

The collaboration includes a phase 1 clinical study involving patients with mild acne, expected to commence in the second quarter of 2025.

In addition, a translational study will be conducted to explore key biological markers that impact acne severity.

The chronic inflammatory skin condition affects a significant portion of the population, with approximately 80% of teenagers and an increasing number of adults—an estimated 40%—experiencing the condition.

Follow the link s for more news on

healthcare research

partnership

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia